RxDoctor Payments Data

Lisa Johnston, NP

Nurse Practitioner · Concord, NCNPI 1760037634

Payments from drug & device makers

$3,436in general payments, 2019–2025

Across 113 payments — averaging $30.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$924
  • Abbott$894
  • Cvrx, Inc.$440
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$392
  • Kestra Medical Technology Services, Inc.$236
  • Boston Scientific$115
  • plus $435 from 8 others

What the payments were for

  • Food & beverage$3,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,436 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$32,533
Medicare patients
202
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten47$394,784
EntrestoSacubitril/Valsartan151$149,575
JardianceEmpagliflozin112$81,561
FarxigaDapagliflozin Propanediol70$72,812
EliquisApixaban68$53,722
XareltoRivaroxaban15$13,596
Torsemide171$7,022
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine14$2,065
Ranolazine ErRanolazine25$1,861
Metoprolol Succinate109$1,202
Spironolactone227$1,160
Potassium Chloride29$904
Furosemide142$733
Carvedilol106$625
Atorvastatin Calcium65$510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$38$394,78447 claims
NovartisEntresto$924$149,575151 claims
Boehringer IngelheimJardiance$23$81,561112 claims
AstraZenecaFarxiga$87$72,81270 claims
Johnson & JohnsonXarelto$75$13,59615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →